PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China.

Authors:
Liu X; Liu Z; Li C; Song X; Wang X and 2 more

Journal:
World J Surg Oncol

Publication Year: 2023

DOI:
10.1186/s12957-023-03178-4

PMCID:
PMC10506239

PMID:
37723497

Journal Information

Full Title: World J Surg Oncol

Abbreviation: World J Surg Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: General Surgery

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateThis retrospective study was approved by the ethics committee of Shandong Frist Medical University and Shandong Academy of Medical Sciences (SDTHEC2022002006) and have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

Evidence found in paper:

"Funding Not applicable."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025